Ceapro Inc V.CZO

COVID and the risk of lung diseases

[prophetoffactz]

This is from new research published in the Lancet this week, based off a massive load of data from the UK Biobank: "Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study"

They found that people who had COVID-19 more than once were more likely to develop asthma, COPD, ILD, and lung cancer compared to those who never had it. They also had a higher risk compared to those who only had one infection.

Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study - eClinicalMedicine (thelancet.com)

[Tencents]

Many studies confirm severe case Covid 19 can lead to such lung conditions  whats changed is the number of incidents - this makes the market potential significantly lower than pandemic conditions would givr funds don't go easily to low patients numbers 

[Ciao]

I can only guess who is trying to spin this, the opportunity was missed 4 years ago with Gilles hiding in Sherbrooke, sheltering (cowering) in place. https://stockhouse.com/companies/bullboard/v.czo/ceapro-inc?postid=35912018

[prophetoffactz]

The risk rises with reinfection and the virus is still everywhere. The virus continues to mutate. One infection, two infections, three infections, on and on. The next ten years could be catastrophic given the burden of disease and that there is no preventative for fibrosis. COVID wasn't around when Avalyn raised its C$80 million going into Phase I testing and PGX-YBG can be used outside the

[Tencents]

Dr kolb sees an interest in lung disease treatment which no doubt his continuing studies will clarify more if it's of interest  The  point is that Covid 19 as a serious health threat hs greatly reduced - hence lung Infractions sourced by the virus will be much limited in numbers compared to what was seen at pandemic levels this means probably funds providers will not be attracted to

[prophetoffactz]

"this means probably funds providers will not be attracted to a projet in this area" There is zero preventative for fibrosis. CZO was receiving significant government money before COVID. It has received significant additional funding due to COVID. The problem with regards to lung fibrosis has only increased since COVID and will continue to increase. It can take decades for disease to

[Tencents]

But I cidents of Covid have reduced drastically - hence funds providers will not be attracted to a much reduced market expectation the future risk of course exists but funds don't run after potential risks . They need to see the disease in place - so Covid related lung disease won't be an attraction the Ceo seems to have made the same conclusion - he has not mentioned Covid as being An